Enrolling CAR-T Trials for Autoimmunity
These Phase 1/2 trials (as of April 2026) target refractory cases (e.g., lupus, scleroderma); eligibility requires failed standard therapies. Check ClinicalTrials.gov for updates/recruitment status.
NOTE: I have no affiliation with these studies - they are public information I am sharing with you! There are contacts for each study listed if you click on the links and most likely will require your doctor’s involvement to refer you to the study.
RESOLUTION (CABA-201)
Diseases: SLE, IIM, SScSponsor/Site: Cabaletta Bio / UChicago Medicine (multi-site, incl. adults 18-75; juvenile dermatomyositis under 18)NCT/Link: NCT05052528
https://clinicaltrials.gov/study/NCT05052528
CD19 CAR-T for Refractory SLE
Diseases: SLESponsor/Site: Various (single-center, Phase 1)NCT/Link: NCT07432334
https://clinicaltrials.gov/study/NCT07432334
CAR-T for Relapsed/Refractory Autoimmune
Diseases: Multiple (SLE, vasculitis, etc.)Sponsor/Site: Single-center (China; dose-escalation)NCT/Link: NCT07193667
https://clinicaltrials.gov/study/NCT07193667
CD20-directed gamma-delta CAR-T
Diseases: SLE, lupus nephritis, SSc, IIM, stiff person syndrome, ANCA vasculitisSponsor/Site: Roswell Park Cancer Center (US, only US site)NCT/Link: Contact Alicia Lieberman, MD
BMS ACTioN CD19 CAR-T
Diseases: SLE, MS, IIM, SSc, MGSponsor/Site: Bristol Myers Squibb (multi-site enrolling)NCT/Link:
https://www.cartautoimmune.com/hcp/clinical-trials
Rapcabtagene Autoleucel (Phase 2)
Diseases: MyositisSponsor/Site: Northwestern (IRB STU00222396)NCT/Link: NCT06665256
https://clinicaltrials.gov/study/NCT06665256
Descartes-08 (AURORA, Phase 3 BCMA mRNA CAR-T)
Diseases: Myasthenia GravisSponsor/Site: Cartesian Therapeutics (outpatient, no chemo)NCT/Link: NCT04146051
https://clinicaltrials.gov/study/NCT04146051
Key Notes
Most US sites: Norton Healthcare (KY), Roswell Park (NY), UChicago, Moffitt (FL opening 2026). Inclusion: Refractory adults; exclude active infections/cancer. Search ClinicalTrials.gov "CAR-T autoimmune recruiting" for latest (119 trials total, many Phase 1). Contact sites directly for screening.